Authorized purpose: cvi42 analyzes cardiovascular CT and MRI with MPR, MIP, volume rendering, centerlines, lumen and stenosis measurements, and reporting for qualified professionals.
Clinical role
Medical-image processing, measurement, quantification, visualization, and reporting support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Heart/Cardiovascular
Key limitation
Keep in mind: For the purpose of obtaining diagnostic information as part of a comprehensive diagnostic decision-making process.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: cvi42 analyzes cardiovascular CT and MRI with MPR, MIP, volume rendering, centerlines, lumen and stenosis measurements, and reporting for qualified professionals.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Heart/Cardiovascular Input: CT and MR images of blood vessels.
Who uses it?Intended users: Qualified medical professionals, experienced in examining and evaluating cardiovascular CT or MR images.
What does the software produce?Output: Combining digital image processing and visualization tools such as multiplaner reconstruction (MPR), thin/think maximum intensity projection (MIP), inverted MIP, volume rendering technique (VRT), curved planner reformation, processing tools such as bone removal and table removal, evaluation tools (vessel centerline calculation, lumen calculation, stenosis calculation) and reporting tools (lesion location, lesion characteristics and key images).
What is its most important limitation?Key limitation: For the purpose of obtaining diagnostic information as part of a comprehensive diagnostic decision-making process.
Clinical takeaway. Clinical role: cvi42 analyzes cardiovascular CT and MRI with MPR, MIP, volume rendering, centerlines, lumen and stenosis measurements, and reporting for qualified professionals.
Evidence takeaway. Evidence from the reviewed source record: K141480 reports software, visualization, centerline, measurement, and reporting validation for the cleared CT and MR cardiovascular functions.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
cvi42 analyzes cardiovascular CT and MRI with MPR, MIP, volume rendering, centerlines, lumen and stenosis measurements, and reporting for qualified professionals.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The readable exact indication establishes CT and MR images as the evaluated image input; it does not establish the current DICOM and release-specific-input wording.
Combining digital image processing and visualization tools such as multiplaner reconstruction (MPR), thin/think maximum intensity projection (MIP), inverted MIP, volume rendering technique (VRT), curved planner reformation, processing tools such as bone removal and table removal, evaluation tools (vessel centerline calculation, lumen calculation, stenosis calculation) and reporting tools (lesion location, lesion characteristics and key images).
Exact FDA submission
Checked 2026-09-19
The readable exact indication lists these processing, visualization, evaluation, and reporting functions; it does not establish the current generalized output list.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K141480 reports software, visualization, centerline, measurement, and reporting validation for the cleared CT and MR cardiovascular functions.
Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K141480 FDA performance package for CVI42
DesignManufacturer software, visualization, and quantitative-measurement validation
PopulationCardiovascular CT and MR analysis workflows
Scopeexact submission
Tested versioncvi42 release cleared in K141480
IndependenceSponsor or vendor study
K141480
Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K141480 by exact submission identifier. This does not exclude product-family or later safety information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT and MR images of blood vessels.
Scope: Exact FDA submission. The readable exact indication establishes CT and MR images as the evaluated image input; it does not establish the current DICOM and release-specific-input wording.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Combining digital image processing and visualization tools such as multiplaner reconstruction (MPR), thin/think maximum intensity projection (MIP), inverted MIP, volume rendering technique (VRT), curved planner reformation, processing tools such as bone removal and table removal, evaluation tools (vessel centerline calculation, lumen calculation, stenosis calculation) and reporting tools (lesion location, lesion characteristics and key images).
Scope: Exact FDA submission. The readable exact indication lists these processing, visualization, evaluation, and reporting functions; it does not establish the current generalized output list.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Combining digital image processing and visualization tools such as multiplaner reconstruction (MPR), thin/think maximum intensity projection (MIP), inverted MIP, volume rendering technique (VRT), curved planner reformation, processing tools such as bone removal and table removal, evaluation tools (vessel centerline calculation, lumen calculation, stenosis calculation) and reporting tools (lesion location, lesion characteristics and key images).
Scope: Exact FDA submission. The readable exact indication lists these processing, visualization, evaluation, and reporting functions; it does not establish the current generalized output list.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
Circle Cardiovascular Imaging describes cvi42's security architecture: all image processing occurs locally within the customer's secure environment with no data transmitted outside the institution, AI models are trained and validated in Circle's controlled environment then locked, frozen and encrypted for deployment, and the deployed AI does not learn from or store customer-site patient data.
Product family
Checked 2026-10-27
Vendor statement. Page scope is the cvi42 product as named; not extended to TruPlan, StrokeSENS, or other Circle products. Exact-release scope is not established.
Only qualified imaging professionals and physicians trained for the represented anatomy and workflow. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Outputs supplement accepted interpretation methods and require review against source images; supported modality, anatomy, protocol, and version limits apply.
DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Outputs supplement accepted interpretation methods and require review against source images; supported modality, anatomy, protocol, and version limits apply.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Outputs supplement accepted interpretation methods and require review against source images; supported modality, anatomy, protocol, and version limits apply.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Radiological images; modality varies or is not specified in FDA list
FDA source
Exact FDA submission
Checked 2026-09-19
The readable exact indication states CT and MR images of blood vessels, not the current unspecified-modality value. Controlled directory display reconciled from exact FDA wording: CT and MR images of blood vessels. -> Radiological images; modality varies or is not specified in FDA list.
The readable exact indication identifies blood vessels; it does not establish the current Heart value. Controlled directory display reconciled from exact FDA wording: Blood vessels. -> Heart/Cardiovascular.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
8Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 20 PubMed and 8 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 8 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
3mensio Workstation is standalone medical-image analysis software for advanced visualization and quantitative analysis of cardiovascular structures. It supports CT, X-ray angiography, and two- and three-dimensional ultrasound DICOM data for planning and sizing cardiovascular interventions, postoperative evaluation, coronary measurements, and calcium scoring.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: ADAS 3D post-processes contrast cardiac MRI and CTA to visualize and quantify myocardial scar and export reviewed results to electrophysiology navigation systems; it is not intended to identify ablation targets.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.